Skip to main
ETON
ETON logo

ETON Stock Forecast & Price Target

ETON Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eton Pharmaceuticals is experiencing significant growth, with a projected 20% year-over-year revenue increase anticipated for 2024, reaching $38.1 million, and a subsequent dramatic growth forecast of 170% to $103.7 million in 2025. The company is also strategically expanding its product pipeline, with expectations for additional revenue from new product launches, including Amglidia, projected to generate $4.2 million in 2027 and increasing to $16.0 million by 2032, pending FDA approval. Furthermore, Eton's management is effectively executing its portfolio expansion strategy, which has led to upward revisions in revenue expectations based on anticipated pricing increases.

Bears say

Eton Pharmaceuticals Inc. is set to incur significant costs, totaling $30.7 million in upfront payments for recent acquisitions, which raises concerns about cash flow management and financial stability. Additionally, the company is facing competitive pressure as management indicates that the acquired products, Increlex and Galzin, are priced lower than rival drugs, potentially impacting revenue generation. This combination of high acquisition costs and pricing competition may adversely affect Eton's profitability and market position moving forward.

ETON has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eton Pharmaceuticals Inc (ETON) Forecast

Analysts have given ETON a Strong Buy based on their latest research and market trends.

According to 3 analysts, ETON has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eton Pharmaceuticals Inc (ETON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.